'Fishy' options trade ahead of Puma news

July 23, 2014 3:00 PM

4 0

Someone bet big in the options market that Puma Biotechnology would be a winner in the days before a positive drug trial sent its stock soaring.

Whether the trading on July 15 is suspicious or not, the report showing a Puma drug's success against breast cancer in a late stage study clearly surprised some Wall Street analysts. Stifel reportedly had predicted a "grim" outlook for the drug, called neratinib, and Cowen said the report showed sup...

Also read: Report: Aroldis Chapman, Yankees reach deal for $86M, 5 years

Read more

To category page

Loading...